Charles Sizemore

Charles Sizemore

Chief Investment Strategist, The Freeport Society

Charles Lewis Sizemore is a market veteran of 20-plus years, dedicated to helping people achieve financial freedom through smart investing.

He holds a Master’s Degree in Finance and Accounting from the London School of Economics and a Bachelor of Business Administration in Finance with an International Emphasis from Texas Christian University in Fort Worth, Texas, where he graduated Magna Cum Laude and as a Phi Beta Kappa scholar.

As a keen market observer, economist, investment analyst, and prolific writer, Charles has been a repeat guest on Fox Business, has been quoted in Barron’s Magazine, and has been featured in numerous well-reputed publications and financial websites, including MarketWatch, TheStreet.com, MSN Money, Seeking Alpha, Stocks, Futures, and Options magazine, The Daily Reckoning, Benzinga, Minyanville, and Investment International.

While Charles enjoys playing basketball and his grandfather’s old saxophone his passion lies in finding investment opportunities that become safe havens for investors navigating this age of chaos.

Learn more about Charles and The Freeport Society’s premium services.

Recent Articles

Your Best Bet for Value: Emerging Markets

By Charles Sizemore, Chief Investment Strategist, The Freeport Society

The market is fleeing momentum stocks in a hurry. Meanwhile, cheaply priced emerging markets like Turkey and Russia are just begging to be bought.

Can Utilities Help You Beat the Market?

By Charles Sizemore, Chief Investment Strategist, The Freeport Society

Award-winning paper discusses 'beta rotation strategy,' which uses the power (and signals) of the utilities sector to determine when you should get defensive.

The Heyday of HFT Is in the Rear-View

By Charles Sizemore, Chief Investment Strategist, The Freeport Society

High-frequency trading won't disappear tomorrow, but the spotlight is a place of weakness for HFT.

3 European Dividend Stocks to Buy

By Charles Sizemore, Chief Investment Strategist, The Freeport Society

A combination of plummeting yields in Europe as well as expected stimulus by the ECB could translate into banner years for these dividend stocks.

JNJ: A Little Leaner, But Is This Dividend Stalwart a Buy?

By Charles Sizemore, Chief Investment Strategist, The Freeport Society

Johnson & Johnson's Ortho-Clinical sale is a bit of a head-scratcher, but it doesn't change the big picture much. JNJ stock still serves a purpose.

Load More